23.52

0.34% -0.08

After Hours: 24.78 1.26 +5.36%

Guardant Health Inc (GH)

Overview News Price History Option Chain Financials Why GH Down? Discussions Forecast

Guardant Health Inc stock is traded at $23.52, with a volume of 2.46M. It is down -0.34% in the last 24 hours and up +6.14% over the past month. Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Previous Close:

$23.60

Open:

$23.41

24h Volume:

2.46M

Relative Volume:

1.20

Market Cap:

$2.89B

Revenue:

$643.81M

Net Income/Loss:

$-490.76M

P/E Ratio:

-5.7931

EPS:

-4.06

Net Cash Flow:

$-299.27M

1W Performance:

+7.94%

1M Performance:

+6.14%

6M Performance:

+24.58%

1Y Performance:

-17.96%

1-Day Range:

$23.27

$24.10

1-Week Range:

$21.28

$24.32

52-Week Range:

$15.81

$37.04

Guardant Health Inc Stock (GH) Company Profile

Name

Guardant Health Inc

Sector

Healthcare (1181)

Industry

Diagnostics & Research (57)

Phone

855-698-8887

Address

3100 HANOVER STREET, PALO ALTO

Employee

1,779

Twitter

@guardanthealth

Next Earnings Date

2024-11-06

Latest SEC Filings

GH's Discussions on Twitter

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-28-23	Initiated	Bernstein	Outperform
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
May-26-23	Upgrade	Citigroup	Neutral → Buy
May-05-23	Initiated	UBS	Buy
Mar-09-23	Downgrade	Citigroup	Buy → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral
Oct-19-22	Initiated	Craig Hallum	Buy
Oct-06-22	Initiated	Stephens	Overweight
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Overweight
Apr-28-22	Resumed	BTIG Research	Buy
Feb-24-22	Reiterated	Canaccord Genuity	Buy
Feb-24-22	Reiterated	Citigroup	Buy
Feb-24-22	Reiterated	Cowen	Outperform
Feb-24-22	Reiterated	Morgan Stanley	Overweight
Feb-24-22	Reiterated	SVB Leerink	Outperform
Feb-24-22	Reiterated	Stifel	Buy
Feb-24-22	Reiterated	Wells Fargo	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Overweight
Jan-11-21	Initiated	Stifel	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jun-12-20	Initiated	BTIG Research	Buy
Feb-21-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Aug-07-19	Reiterated	Canaccord Genuity	Buy
Apr-16-19	Initiated	Canaccord Genuity	Buy
Apr-10-19	Upgrade	BofA/Merrill	Neutral → Buy
Feb-28-19	Reiterated	BofA/Merrill	Neutral
Oct-29-18	Initiated	BofA/Merrill	Neutral
Oct-29-18	Initiated	JP Morgan	Overweight
Oct-29-18	Initiated	William Blair	Outperform

View All

Guardant Health Inc Stock (GH) Latest News

09:15 AM

Unveiling Guardant Health (GH) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance

09:15 AM

Nov 04, 2024